Trevena, Inc. Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain
Published: Feb 13, 2012
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain. TRV130 is a biased ligand that targets the mu-opioid receptor to optimize analgesia while minimizing mu opioid receptor-mediated side effects such as respiratory suppression and constipation. As a biased ligand, TRV130 activates the G-protein signaling pathway mediated by the mu-opioid receptor while antagonizing the ß-arrestin pathway. In preclinical studies, TRV130 was powerfully analgesic with an improved safety and tolerability profile when compared directly to classical opioids such as morphine.